Commerzbank Aktiengesellschaft FI Purchases 8,000 Shares of Zoetis Inc. $ZTS

Commerzbank Aktiengesellschaft FI lifted its position in Zoetis Inc. (NYSE:ZTS) by 259.7% during the 4th quarter, Holdings Channel reports. The firm owned 11,081 shares of the company’s stock after buying an additional 8,000 shares during the quarter. Commerzbank Aktiengesellschaft FI’s holdings in Zoetis were worth $1,394,000 at the end of the most recent reporting period.

Several other large investors have also made changes to their positions in ZTS. RFG Advisory LLC grew its stake in shares of Zoetis by 4.9% during the 4th quarter. RFG Advisory LLC now owns 1,708 shares of the company’s stock worth $215,000 after acquiring an additional 80 shares during the period. YANKCOM Partnership grew its stake in shares of Zoetis by 3.5% during the 4th quarter. YANKCOM Partnership now owns 2,402 shares of the company’s stock worth $302,000 after acquiring an additional 81 shares during the period. Evergreen Capital Management LLC grew its stake in shares of Zoetis by 3.3% during the 3rd quarter. Evergreen Capital Management LLC now owns 2,696 shares of the company’s stock worth $394,000 after acquiring an additional 85 shares during the period. Beese Fulmer Investment Management Inc. grew its stake in shares of Zoetis by 2.4% during the 3rd quarter. Beese Fulmer Investment Management Inc. now owns 3,672 shares of the company’s stock worth $537,000 after acquiring an additional 85 shares during the period. Finally, Quest 10 Wealth Builders Inc. grew its stake in shares of Zoetis by 4.7% during the 4th quarter. Quest 10 Wealth Builders Inc. now owns 1,904 shares of the company’s stock worth $240,000 after acquiring an additional 86 shares during the period. Institutional investors own 92.80% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on ZTS shares. BTIG Research reiterated a “buy” rating and set a $160.00 price target on shares of Zoetis in a research note on Thursday, February 26th. Citigroup began coverage on Zoetis in a research note on Wednesday, April 15th. They issued a “buy” rating and a $145.00 target price for the company. Wall Street Zen downgraded Zoetis from a “buy” rating to a “hold” rating in a research note on Saturday, May 2nd. UBS Group cut their target price on Zoetis from $130.00 to $99.00 and set a “neutral” rating for the company in a research note on Friday, May 8th. Finally, William Blair restated an “outperform” rating on shares of Zoetis in a research note on Monday, March 2nd. Seven research analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Zoetis presently has a consensus rating of “Hold” and a consensus target price of $137.50.

Zoetis Stock Down 1.8%

Shares of NYSE ZTS opened at $74.11 on Friday. Zoetis Inc. has a 52 week low of $72.38 and a 52 week high of $172.23. The business has a 50-day simple moving average of $112.28 and a two-hundred day simple moving average of $120.94. The company has a quick ratio of 1.91, a current ratio of 3.15 and a debt-to-equity ratio of 2.80. The company has a market cap of $31.07 billion, a P/E ratio of 12.29, a P/E/G ratio of 1.21 and a beta of 0.87.

Zoetis (NYSE:ZTS) last issued its quarterly earnings results on Thursday, May 7th. The company reported $1.53 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.60 by ($0.07). The business had revenue of $2.26 billion for the quarter, compared to the consensus estimate of $2.30 billion. Zoetis had a net margin of 27.80% and a return on equity of 66.85%. The business’s revenue was up 2.9% compared to the same quarter last year. During the same quarter last year, the business posted $1.48 EPS. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. Research analysts anticipate that Zoetis Inc. will post 6.91 earnings per share for the current fiscal year.

Insider Activity

In other Zoetis news, Director Frank A. Damelio purchased 6,650 shares of the company’s stock in a transaction dated Wednesday, May 13th. The stock was purchased at an average price of $75.39 per share, for a total transaction of $501,343.50. Following the transaction, the director owned 21,458 shares in the company, valued at $1,617,718.62. The trade was a 44.91% increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Michael B. Mccallister purchased 3,000 shares of the company’s stock in a transaction dated Monday, May 11th. The shares were acquired at an average price of $77.76 per share, with a total value of $233,280.00. Following the transaction, the director owned 24,524 shares in the company, valued at approximately $1,906,986.24. The trade was a 13.94% increase in their position. The disclosure for this purchase is available in the SEC filing. In the last 90 days, insiders acquired 11,650 shares of company stock worth $886,384. 0.22% of the stock is currently owned by insiders.

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.